Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Damages

At this point, I'd accept no less than $0.50/share in damages.

Add to that going forward with dividends from new licenses and growth in share price.

Lingering questions going forward: So the lists are split, do we still share the revenues no matter who bags a license? Does PDS still approve each and every license?

Share
New Message
Please login to post a reply